Literature DB >> 7193087

Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase.

J A Kuhn, W P Argy, T A Rakowski, J K Moriarty, G E Schreiner, P S Schein.   

Abstract

Urinary beta-glucuronidase activity as a measure of renal tubular damage was studied in 23 patients receiving 43 courses of cis-diamminedichloroplatinum(II) therapy. A 250% increase in urinary beta-glucuronidase activity was noted after therapy, compared with values before therapy. There were no patients who sustained renal insufficiency as evidenced by more commonly used and coarser parameters of renal function. This marked rise in urinary beta-glucuronidase activity was felt to indicate tubular toxicity due to the cis-diamminedichloroplatinum(II) not measured by the usual parameters of renal function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7193087

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.

Authors:  Takayuki Takimoto; Tasuku Nakabori; Akio Osa; Satomu Morita; Haruko Terada; Susumu Oseto; Takashi Iwazawa; Kinya Abe
Journal:  Int J Clin Oncol       Date:  2011-08-19       Impact factor: 3.402

3.  Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

Authors:  L Pendyala; S Madajewicz; S B Lele; S G Arbuck; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.

Authors:  A S Tirelli; N Colombo; G Cavanna; C Mangioni; B M Assael
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

Authors:  M P Goren; R K Wright; M E Horowitz
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.